Debjit Chattopadhyay Analyst PerformanceSenior Managing Director at GuggenheimDebjit Chattopadhyay is a stock analyst at Guggenheim focused in the medical sector, covering 57 publicly traded companies. Over the past year, Debjit Chattopadhyay has issued 24 stock ratings, including and buy recommendations. While full access to Debjit Chattopadhyay's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Debjit Chattopadhyay's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings417 Last 11 YearsBuy Recommendations88.65% 367 Buy RatingsCompanies Covered57 Unique Companies Ratings Distribution414RatingsDistribution of strong buy, buy, hold, and sell ratings by Debjit Chattopadhyay.RatingPercentageCount Strong Buy0.0%0 ratings Buy88.6%367 ratings Hold11.1%46 ratings Sell0.2%1 ratingsOut of 414 total stock ratings issued by Debjit Chattopadhyay at Guggenheim, the majority (88.6%) have been Buy recommendations, followed by 11.1% Hold and 0.2% Sell.Best & Worst CallsBest Call0000.0%THORNov 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%PTCTMar 2015Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ94.7% of companies on NASDAQ54 companiesNYSE3.5% of companies on NYSE2 companiesOTCMKTS1.8% of companies on OTCMKTS1 companyDebjit Chattopadhyay, an analyst at Guggenheim, currently covers 57 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical55 companies96.5%Energy1 company1.8%Miscellaneous1 company1.8%Debjit Chattopadhyay of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on Energy and companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE30 companies52.6%PHARMACEUTICAL PREPARATIONS8 companies14.0%MED - DRUGS6 companies10.5%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC6 companies10.5%BIOTECHNOLOGY3 companies5.3%MED PRODUCTS1 company1.8%PETROLEUM REFINING1 company1.8%DIAGNOSTIC SUBSTANCES1 company1.8%Miscellaneous1 company1.8% Debjit Chattopadhyay's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSRPTSarepta Therapeutics9/15/2025Reiterated Rating$17.39$22.00Buy$0.0000.00% ROIMAZEMaze Therapeutics9/15/2025Boost Price Target$23.30$34.00Buy$0.0000.00% ROIPEPGPepGen9/9/2025Initiated Coverage$1.49$6.00Buy$0.0000.00% ROISLNOSoleno Therapeutics8/27/2025Reiterated Rating$69.77$106.00Buy$0.0000.00% ROINTLAIntellia Therapeutics8/13/2025Reiterated Rating$10.86$14.00Buy$0.0000.00% ROISLNOSoleno Therapeutics8/7/2025Boost Price Target$80.99$106.00Buy$0.0000.00% ROIVRTXVertex Pharmaceuticals8/6/2025Lower Price Target$387.47$546.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical8/6/2025Boost Price Target$61.27$106.00Buy$0.0000.00% ROIRAREUltragenyx Pharmaceutical6/20/2025Reiterated Rating$36.88$64.00Buy$0.0000.00% ROIDYNDyne Therapeutics6/18/2025Reiterated Rating$11.00$50.00Buy$0.0000.00% ROIQUREuniQure5/12/2025Reiterated Rating$12.76$28.00Buy$0.0000.00% ROINTLAIntellia Therapeutics5/12/2025Lower Price Target$8.71$45.00Buy$0.0000.00% ROISLNOSoleno Therapeutics5/8/2025Boost Price Target$78.63$97.00Buy$0.0000.00% ROIKRYSKrystal Biotech5/7/2025Lower Price Target$136.13$189.00Buy$0.0000.00% ROIBEAMBeam Therapeutics5/7/2025Lower Price Target$15.70$55.00Buy$0.0000.00% ROISRPTSarepta Therapeutics5/7/2025Lower Price Target$37.57$98.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals5/1/2025Lower Price Target$31.98$64.00Buy$0.0000.00% ROIIONSIonis Pharmaceuticals4/3/2025Reiterated Rating$27.98Buy$0.0000.00% ROISLNOSoleno Therapeutics3/28/2025Reiterated Rating$67.39$81.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals3/26/2025Reiterated Rating$14.83$28.00Buy$0.0000.00% ROIBEAMBeam Therapeutics2/27/2025Reiterated Rating$29.04$78.00Buy$0.0000.00% ROIMAZEMaze Therapeutics2/25/2025Initiated Coverage$11.33$19.00Buy$0.0000.00% ROICNTACentessa Pharmaceuticals2/10/2025Reiterated Rating$19.03Buy$0.0000.00% ROIDYNDyne Therapeutics1/24/2025Reiterated Rating$13.50Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
